Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.83 |
| ▸ | GAA | P10253 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891915 | 0.91 | POLB (1.00) | POLBGAANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5843614 | 0.91 | POLB (1.00) | POLBGAANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23177789 | 0.91 | POLB (1.00) | POLBGAANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21948970 | 0.88 | POLB (0.71) | POLBGAANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL4005026 | 0.86 | POLB (0.69) | POLBGAANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL17184642 | 0.82 | POLB (0.59) | POLBGAANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16750068 | 0.82 | POLB (0.63) | POLBGAANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL15878150 | 0.81 | POLB (0.57) | POLBGAANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23236621 | 0.81 | POLB (0.57) | POLBGAANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15877734 | 0.81 | POLB (0.57) | POLBGAANPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| EP-4114375-A1 | FERROPTOSIS INHIBITORS-DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd (KY) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022268520-A1 | USE OF SUBSTITUTED PYRROLIDINONES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE OF PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | WO | disclosed |
| CN-115151252-A | Iron death inhibitors diarylamine para-acetamides | 维泰瑞隆有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2015161016-A1 | BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161014-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-8293757-B2 | 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-8293757-B2 | 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| CN-101945655-A | 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators | GLAXO GROUP LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| EP-2231153-A2 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077559-A2 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009026276-A1 | 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | P2RX3, P2RX6, P2RX7 | POLB 4684/4885GAA 4657/4885NPSR1 126/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | POLB 4641/4885GAA 4193/4885NPSR1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.